{
    "clinical_study": {
        "@rank": "98962", 
        "arm_group": [
            {
                "arm_group_label": "Belatacept treated adult kidney-only transplant recipients", 
                "description": "All adult kidney-only transplant recipients treated with Nulojix (Belatacept)"
            }, 
            {
                "arm_group_label": "CNIs at transplantation"
            }
        ], 
        "brief_summary": {
            "textblock": "-  The prevalence of Belatacept use\n\n        -  The characteristics of Belatacept users and the temporal trends in these\n           characteristics\n\n        -  Characteristics of adult kidney-only transplant recipients who are treated with\n           Belatacept vs. who are treated with Calcineurin inhibitors (CNI)-based regimens at the\n           time of transplantation, and the temporal trends in these characteristics during 7\n           years post approval of Belatacept."
        }, 
        "brief_title": "Pattern Of Use Of Belatacept In US Transplant Recipients", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Transplantation: Transplantation, Kidney", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The cohort for the analyses of all transplants includes all organ transplant\n             recipients who are reported with Belatacept at transplant\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The cohort for the analyses of all transplants includes all organ transplant recipients\n        who are reported with Belatacept at transplant"
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670058", 
            "org_study_id": "IM103-074"
        }, 
        "intervention_browse": {
            "mesh_term": "Abatacept"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 20, 2012", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "number_of_groups": "2", 
        "official_title": "Pattern Of Use Of Belatacept In US Transplant Recipients", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Timeframe: Every 6 months up to 72 months", 
                "measure": "The prevalence of Belatacept use", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 months"
            }, 
            {
                "description": "EBV = Epstein-Barr virus; CMV = cytomegalovirus; Timeframe: Every 6 months up to 72 months", 
                "measure": "Characteristics of Belatacept users, in terms of age, sex, ethnicity, transplanted organs, donor EBV infection-recipient EBV serostatus, donor CMV infection-recipient CMV serostatus, and the temporal trends in these characteristics", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 months"
            }, 
            {
                "description": "Characteristics of adult kidney-only transplant recipients  assessed are age, sex, ethnicity, EBV serostatus, CMV serostatus, organ characteristics, concomitant immunosuppressive medication use, and type of induction medication use.\nCNI = calcineurin inhibitors; Timeframe: Every 6 months up to 72 months", 
                "measure": "Characteristics of adult kidney-only transplant recipients who are treated with Belatacept vs. who are treated with CNI-based regimens at the time of transplantation and temporal trends in these characteristics during 7 years post approval of Belatacept", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characteristics of adult, EBV seropositive, kidney-only transplant recipients assessed are age, sex, ethnicity, CMV serostatus, organ characteristics, concomitant immunosuppressive medication use, and type of induction medication use", 
                "measure": "Characteristics of adult EBV seropositive kidney-only transplant recipients treated with Belatacept vs who are treated with CNI-based regimens at time of transplantation & temporal trends in these characteristics during 7 yrs post approval of Belatacept", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }, 
            {
                "measure": "Extent of switches to or from Belatacept within one year post-transplant in adult, kidney-only transplant recipients", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }, 
            {
                "measure": "Characteristics of switchers vs. non-switchers (age, sex, ethnicity, EBV serostatus, CMV serostatus, organ characteristics, concomitant immunosuppressive medication use, and type of induction medication use)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }, 
            {
                "measure": "Temporal trend in switches during 7 years post-approval", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }, 
            {
                "measure": "CMV treatment/prophylaxis by CMV serostatus in adult kidney-only transplant recipients who had anti-CMV therapy data recorded in United Network for Organ Sharing (UNOS) and treated with Belatacept vs. CNIs at transplantation", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }, 
            {
                "measure": "CMV treatment/prophylaxis by CMV serostatus in adult kidney-only transplant recipients who had anti-CMV therapy data recorded in UNOS and switched to Belatacept, switched from Belatacept, or did not switch", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }, 
            {
                "measure": "Characteristics of Belatacept users stratified by EBV serostatus, including age, sex, ethnicity, general medical factors, transplant history (organ, date, graft failure date), and donor organ characteristics", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months up to 72 months"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}